Cargando…

Pharmacological basis of bergapten in gastrointestinal diseases focusing on H(+)/K(+) ATPase and voltage-gated calcium channel inhibition: A toxicological evaluation on vital organs

Aim and objectives: This study aimed to establish a pharmacological basis for evaluating the effects of bergapten (5-methoxypsoralen) in gastrointestinal diseases and assessment of its toxicological profile. Methods: The pharmacokinetic profile was evaluated using the SwissADME tool. AUTODOCK and Py...

Descripción completa

Detalles Bibliográficos
Autores principales: Aslam, Huma, Khan, Arif-ullah, Qazi, Neelum Gul, Ali, Fawad, Hassan, Syed Shams ul, Bungau, Simona
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9709249/
https://www.ncbi.nlm.nih.gov/pubmed/36467058
http://dx.doi.org/10.3389/fphar.2022.1005154
_version_ 1784841107550502912
author Aslam, Huma
Khan, Arif-ullah
Qazi, Neelum Gul
Ali, Fawad
Hassan, Syed Shams ul
Bungau, Simona
author_facet Aslam, Huma
Khan, Arif-ullah
Qazi, Neelum Gul
Ali, Fawad
Hassan, Syed Shams ul
Bungau, Simona
author_sort Aslam, Huma
collection PubMed
description Aim and objectives: This study aimed to establish a pharmacological basis for evaluating the effects of bergapten (5-methoxypsoralen) in gastrointestinal diseases and assessment of its toxicological profile. Methods: The pharmacokinetic profile was evaluated using the SwissADME tool. AUTODOCK and PyRx were used for evaluating the binding affinities. The obtained results were further investigated for a post-dock analysis using Discovery Studio Visualizer 2016. The Desmond software package was used to conduct molecular dynamic simulations of best bound poses. Bergapten was further investigated for antidiarrheal, anti-secretory, charcoal meal transit time, anti-ulcer, anti-H. pylori activity. Results: Bergapten at a dose of 50, 100, and 200 mg/kg was proved effective in reducing diarrheal secretions, intestinal secretions, and distance moved by charcoal meal. Bergapten at the aforementioned doses acts as a gastroprotective agent in the ethanol-induced ulcer model that can be attributed to its effectiveness against H. pylori. Bergapten shows concentration-dependent relaxation of both spontaneous and K(+) (80 mM)-induced contractions in the isolated rabbit jejunum model; the Ca(2+) concentration–response curves (CRCs) were shifted to the right showing potentiating effect similar to papaverine. For molecular investigation, the H(+)/K(+) ATPase inhibitory assay indicated inhibition of the pump comparable to omeprazole. Oxidative stress markers GST, GSH, and catalase showed increased expression, whereas the expression of LPO (lipid peroxidation) was reduced. Histopathological examination indicated marked improvement in cellular morphology. ELISA and western blot confirmed the reduction in inflammatory mediator expression. RT-PCR reduced the mRNA expression level of H(+)/K(+) ATPase, confirming inhibition of the pump. The toxicological profile of bergapten was evaluated by an acute toxicity assay and evaluated for behavioral analysis, and the vital organs were used to analyze biochemical, hematological, and histopathological examination. Conclusion: Bergapten at the tested doses proved to be an antioxidant, anti-inflammatory, anti-ulcer, and antidiarrheal agent and relatively safe in acute toxicity assay.
format Online
Article
Text
id pubmed-9709249
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-97092492022-12-01 Pharmacological basis of bergapten in gastrointestinal diseases focusing on H(+)/K(+) ATPase and voltage-gated calcium channel inhibition: A toxicological evaluation on vital organs Aslam, Huma Khan, Arif-ullah Qazi, Neelum Gul Ali, Fawad Hassan, Syed Shams ul Bungau, Simona Front Pharmacol Pharmacology Aim and objectives: This study aimed to establish a pharmacological basis for evaluating the effects of bergapten (5-methoxypsoralen) in gastrointestinal diseases and assessment of its toxicological profile. Methods: The pharmacokinetic profile was evaluated using the SwissADME tool. AUTODOCK and PyRx were used for evaluating the binding affinities. The obtained results were further investigated for a post-dock analysis using Discovery Studio Visualizer 2016. The Desmond software package was used to conduct molecular dynamic simulations of best bound poses. Bergapten was further investigated for antidiarrheal, anti-secretory, charcoal meal transit time, anti-ulcer, anti-H. pylori activity. Results: Bergapten at a dose of 50, 100, and 200 mg/kg was proved effective in reducing diarrheal secretions, intestinal secretions, and distance moved by charcoal meal. Bergapten at the aforementioned doses acts as a gastroprotective agent in the ethanol-induced ulcer model that can be attributed to its effectiveness against H. pylori. Bergapten shows concentration-dependent relaxation of both spontaneous and K(+) (80 mM)-induced contractions in the isolated rabbit jejunum model; the Ca(2+) concentration–response curves (CRCs) were shifted to the right showing potentiating effect similar to papaverine. For molecular investigation, the H(+)/K(+) ATPase inhibitory assay indicated inhibition of the pump comparable to omeprazole. Oxidative stress markers GST, GSH, and catalase showed increased expression, whereas the expression of LPO (lipid peroxidation) was reduced. Histopathological examination indicated marked improvement in cellular morphology. ELISA and western blot confirmed the reduction in inflammatory mediator expression. RT-PCR reduced the mRNA expression level of H(+)/K(+) ATPase, confirming inhibition of the pump. The toxicological profile of bergapten was evaluated by an acute toxicity assay and evaluated for behavioral analysis, and the vital organs were used to analyze biochemical, hematological, and histopathological examination. Conclusion: Bergapten at the tested doses proved to be an antioxidant, anti-inflammatory, anti-ulcer, and antidiarrheal agent and relatively safe in acute toxicity assay. Frontiers Media S.A. 2022-11-16 /pmc/articles/PMC9709249/ /pubmed/36467058 http://dx.doi.org/10.3389/fphar.2022.1005154 Text en Copyright © 2022 Aslam, Khan, Qazi, Ali, Hassan and Bungau. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Aslam, Huma
Khan, Arif-ullah
Qazi, Neelum Gul
Ali, Fawad
Hassan, Syed Shams ul
Bungau, Simona
Pharmacological basis of bergapten in gastrointestinal diseases focusing on H(+)/K(+) ATPase and voltage-gated calcium channel inhibition: A toxicological evaluation on vital organs
title Pharmacological basis of bergapten in gastrointestinal diseases focusing on H(+)/K(+) ATPase and voltage-gated calcium channel inhibition: A toxicological evaluation on vital organs
title_full Pharmacological basis of bergapten in gastrointestinal diseases focusing on H(+)/K(+) ATPase and voltage-gated calcium channel inhibition: A toxicological evaluation on vital organs
title_fullStr Pharmacological basis of bergapten in gastrointestinal diseases focusing on H(+)/K(+) ATPase and voltage-gated calcium channel inhibition: A toxicological evaluation on vital organs
title_full_unstemmed Pharmacological basis of bergapten in gastrointestinal diseases focusing on H(+)/K(+) ATPase and voltage-gated calcium channel inhibition: A toxicological evaluation on vital organs
title_short Pharmacological basis of bergapten in gastrointestinal diseases focusing on H(+)/K(+) ATPase and voltage-gated calcium channel inhibition: A toxicological evaluation on vital organs
title_sort pharmacological basis of bergapten in gastrointestinal diseases focusing on h(+)/k(+) atpase and voltage-gated calcium channel inhibition: a toxicological evaluation on vital organs
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9709249/
https://www.ncbi.nlm.nih.gov/pubmed/36467058
http://dx.doi.org/10.3389/fphar.2022.1005154
work_keys_str_mv AT aslamhuma pharmacologicalbasisofbergapteningastrointestinaldiseasesfocusingonhkatpaseandvoltagegatedcalciumchannelinhibitionatoxicologicalevaluationonvitalorgans
AT khanarifullah pharmacologicalbasisofbergapteningastrointestinaldiseasesfocusingonhkatpaseandvoltagegatedcalciumchannelinhibitionatoxicologicalevaluationonvitalorgans
AT qazineelumgul pharmacologicalbasisofbergapteningastrointestinaldiseasesfocusingonhkatpaseandvoltagegatedcalciumchannelinhibitionatoxicologicalevaluationonvitalorgans
AT alifawad pharmacologicalbasisofbergapteningastrointestinaldiseasesfocusingonhkatpaseandvoltagegatedcalciumchannelinhibitionatoxicologicalevaluationonvitalorgans
AT hassansyedshamsul pharmacologicalbasisofbergapteningastrointestinaldiseasesfocusingonhkatpaseandvoltagegatedcalciumchannelinhibitionatoxicologicalevaluationonvitalorgans
AT bungausimona pharmacologicalbasisofbergapteningastrointestinaldiseasesfocusingonhkatpaseandvoltagegatedcalciumchannelinhibitionatoxicologicalevaluationonvitalorgans